Begin main content

Reports

We found 5788 result(s)

upadacitinib (TBC)

Last Updated: October 18, 2019
Result type: Reports
Product Line: Common Drug Review
Generic Name: upadacitinib
Indications: Arthritis, Rheumatoid

  • Brand Name: TBC
  • Manufacturer: AbbVie
  • Project Number: SR0614-000
  • Project Status: Active
  • Submission Type: New

icosapent ethyl (Vascepa)

Last Updated: October 18, 2019
Result type: Reports
Product Line: Common Drug Review
Generic Name: icosapent ethyl
Indications: Ischemic events in statin-treated patients

  • Brand Name: Vascepa
  • Manufacturer: HLS Therapeutics
  • Project Number: SR0619-000
  • Project Status: Active
  • Submission Type: New

tafamidis (TBC)

Last Updated: October 17, 2019
Result type: Reports
Product Line: Common Drug Review
Generic Name: tafamidis
Indications: transthyretin-mediated amyloidosis

  • Brand Name: TBC
  • Manufacturer: Pfizer Canada
  • Project Number: SR0625-000
  • Project Status: Active
  • Submission Type: New

insulin degludec + liraglutide (Xultophy)

Last Updated: October 17, 2019
Result type: Reports
Product Line: Common Drug Review
Generic Name: insulin degludec + liraglutide
Indications: Diabetes mellitus, Type 2

  • Brand Name: Xultophy
  • Manufacturer: Novo Nordisk Canada Inc.
  • Project Number: SR0599-000
  • Project Status: Active
  • Submission Type: New Combination

inotersen (Tegsedi)

Last Updated: October 18, 2019
Result type: Reports
Product Line: Common Drug Review
Generic Name: inotersen
Indications: hereditary transthyretin amyloidosis

  • Brand Name: Tegsedi
  • Manufacturer: Akcea Therapeutics Inc.
  • Project Number: SR0603-000
  • Project Status: Active
  • Submission Type: New

onabotulinumtoxinA (Botox)

Last Updated: October 17, 2019
Result type: Reports
Product Line: Common Drug Review
Generic Name: onabotulinumtoxinA
Indications: Migraine, chronic

  • Brand Name: Botox
  • Manufacturer: Allergan Canada Inc.
  • Project Number: SR0584-000
  • Project Status: Active
  • Submission Type: Resubmission

Care for Acquired Brain Injury and Concurrent Mental Health and Substance Use Issues

Last Updated: October 18, 2019
Result type: Reports
Product Line: Environmental Scans

CADTH is undertaking an Environmental Scan of systems and services that are in place in Canada for caring for individuals affected by acquired brain injury (ABI) and concurrent mental health and/or substance use issues. This project is being conducted to help inform decision-making and support practice change to improve the health and well-being...

  • Project Number: ES0339-000

Dosing and Timing of Immuno-Oncology Drugs

Last Updated: October 18, 2019
Result type: Reports
Product Line: Optimal Use, Technology Review

Immuno-oncology (IO) drugs (also called immune checkpoint inhibitors or immunotherapy drugs) have transformed the field of cancer. These drugs have elicited unprecedented therapeutic responses, allowing significant regression and sometimes resolution of several cancer types. Dosing of IO therapies investigated in clinical trials is inconsistent ...

  • Project Number: HO0008-000

Health Technology Update — Issue 24

Last Updated: October 18, 2019
Result type: Reports
Product Line: Health Technology Update
opens in document viewer

This issue of Health Technology Update features brief summaries of information on a range of technologies that aim to support older adults and facilitate aging in place — from ingestible sensors for medication monitoring to a virtual reality-inspired exercise bike. These technologies were identified through the CADTH Horizon Scanning Service ...

  • Project Number: EN0014-000